Immunotherapy of cancer tumors with inhibition of PD-1 membrane protein and its ligands interaction
The identification of the PD-1 receptor by Tasuku Honjo and CTLA-4 by James Ellison marked the beginning of the study of new regulatory pathways activating the immune response. The term “immune checkpoints” was introduced to denote the system of inhibitory mechanisms that include these proteins. The...
Guardado en:
Autores principales: | A. V. Chetveryakov, V. L. Tsepelev |
---|---|
Formato: | article |
Lenguaje: | RU |
Publicado: |
Scientific Сentre for Family Health and Human Reproduction Problems
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/ea6c4a1bb2ae4dbe9e16de4c96530ab5 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
INFLUENCE OF ANTIBODIES AGAINST CTLA-4 AND PD-1 UPON QUANTITIES OF THEIR TARGET RECEPTORS
por: I. O. Chikileva, et al.
Publicado: (2019) -
Immunoexpression of PD-L1 and PD-1 and Its Clinicopathological Correlation in Urothelial Carcinomas
por: Utpal Kumar, et al.
Publicado: (2021) -
Current Progress and Future Perspectives of Immune Checkpoint in Cancer and Infectious Diseases
por: Xin Cai, et al.
Publicado: (2021) -
The Role of the Tumor Microenvironment and Treatment Strategies in Colorectal Cancer
por: Yaping Chen, et al.
Publicado: (2021) -
Relationship between Tumor Mutational Burden, PD-L1, Patient Characteristics, and Response to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma
por: Kimberly M. Burcher, et al.
Publicado: (2021)